Welcome to our dedicated page for Lisata Therapeutics news (Ticker: LSTA), a resource for investors and traders seeking the latest updates and insights on Lisata Therapeutics stock.
Lisata Therapeutics, Inc. (Nasdaq: LSTA) is a clinical-stage pharmaceutical company developing certepetide-based therapies for advanced solid tumors and other serious diseases. This news page aggregates company announcements, clinical trial updates and regulatory disclosures so readers can follow how Lisata’s certepetide program and related partnerships evolve over time.
Lisata’s recent news flow has focused on progress across multiple certepetide clinical studies, including the ASCEND Phase 2b trial in metastatic pancreatic ductal adenocarcinoma, the BOLSTER Phase 2a trial in cholangiocarcinoma, the CENDIFOX Phase 1b/2a trial in pancreatic, colon and appendiceal cancers, the iLSTA Phase 1b/2a trial in locally advanced non-resectable pancreatic ductal adenocarcinoma and a Phase 2a glioblastoma multiforme study. Press releases have highlighted preliminary efficacy and safety signals, tumor microenvironment findings and timelines for upcoming data readouts.
Investors and researchers can also see updates on Lisata’s business development activities, such as its global non-exclusive license agreement with Catalent, Inc. to use certepetide as a SMARTag® antibody-drug conjugate payload, and its strategic alliance with GATC Health to apply an AI-powered Multiomics Advanced Technology™ platform to drug discovery. Financial results releases provide context on operating expenses, cash runway and the company’s ability to support ongoing trials.
By reviewing the LSTA news feed on this page, readers can monitor clinical milestones, conference presentations, licensing developments and other corporate communications directly sourced from Lisata’s public announcements and related SEC-referenced materials.
Lisata Therapeutics (Nasdaq: LSTA) announced a mutual termination of its February 2021 Exclusive License and Collaboration Agreement with Qilu Pharmaceutical, causing all licenses and rights for certepetide in the Greater China region to revert to Lisata.
The original agreement had granted Qilu exclusive development and commercialization rights in Mainland China, Hong Kong, Macau, and Taiwan; those rights now return to Lisata following the termination. Qilu remains responsible for completing and winding down an ongoing Phase 2 clinical study (NCT06261359) of certepetide with chemotherapy in metastatic pancreatic ductal adenocarcinoma. Lisata will negotiate with Qilu about potential licensing of relevant trial data.
Lisata Therapeutics (Nasdaq: LSTA) entered a binding term sheet to be acquired by Kuva Labs in an all-cash tender offer of $4.00 per share. Stockholders will also receive two non-tradeable contingent value rights (CVRs) worth $1.00 each payable upon (1) reversion of certain Greater China rights and (2) Kuva filing an NDA or similar registration for certepetide.
The boards of both companies approved the term sheet unanimously and expect a definitive purchase agreement prior to February 27, 2026. The cash offer is an approximate 85% premium to the most recent close and, including both CVRs, an approximate 180% premium.
Lisata Therapeutics (Nasdaq: LSTA) reported Q3 2025 results and a business update on Nov 6, 2025. The company reported $19.0 million in cash and expects that available funds will fund operations into the first quarter of 2027. Operating expenses for Q3 were $4.4 million with a net loss of $4.2 million versus $4.9 million a year earlier.
Clinical progress: positive preliminary and pooled data from ASCEND (including four complete responses in treated patients), corroborative data from iLSTA, and encouraging surgical and survival signals from CENDIFOX (50% R0 resection, 70% pathologic partial response, 60% two-year OS in the PDAC subset). Business deals include a global nonexclusive license with Catalent to evaluate certepetide in ADCs and a strategic alliance with GATC Health for AI-driven discovery.
Lisata Therapeutics (Nasdaq: LSTA) won Overall BioPharma Solution of the Year at the 2025 BioTech Breakthrough Awards on Nov 6, 2025, marking its second consecutive year receiving a BioTech Breakthrough Award.
Lisata is a clinical-stage company using its CendR Platform® to enhance tumor-targeted, tissue-penetrating delivery of anti-cancer therapies. Recent clinical highlights include ASCEND Phase 2b high-dose results showing 6‑month PFS 60.8% vs 25% placebo and ORR 45.2% vs 19% placebo, and the iLSTA trial reporting 60% ORR and 100% disease control rate in locally advanced, non-resectable pancreatic cancer, including a complete response.
Lisata Therapeutics (Nasdaq: LSTA) highlighted positive preclinical results on November 4, 2025 after Catalent presented data at the 16th Annual World ADC San Diego Conference (Nov 3–6, 2025).
Catalent reported that incorporating Lisata’s proprietary iRGD cyclic peptide certepetide as a non-cytotoxic payload in its SMARTag® ADC platform improved tumor-selective penetration and broadened intratumoral distribution of cytotoxic payloads, and also enhanced ADC efficacy in preclinical models. Lisata emphasized this finding as supportive of its licensing partnership with Catalent and its strategy to use certepetide to boost therapeutic delivery across modalities.
Lisata Therapeutics (Nasdaq: LSTA) will report third quarter 2025 financial results for the period ended September 30, 2025 on Thursday, November 6, 2025 after market close.
The company will host a conference call at 4:30 p.m. Eastern time the same day. Participants are encouraged to dial in 10 minutes early. Dial-in numbers: toll-free (800) 715-9871, toll/intl (646) 307-1963 with Conference ID 6375221. A live webcast will be available under the Investors & News section of Lisata’s website, with a replay posted two hours after the call and accessible for 12 months.
Lisata Therapeutics (NASDAQ:LSTA) will present a corporate overview at LD Micro Main Event XIX in San Diego, California, taking place October 19–21, 2025. David J. Mazzo, Ph.D., President and CEO, is scheduled to present on Monday, October 20 at 10:30 a.m. PT. One-on-one investor meetings will be held throughout the conference. The presentation will be available for online viewing and interested parties can request meeting information or schedule a one-on-one by emailing jmenditto@lisata.com.
Lisata Therapeutics (Nasdaq: LSTA) and Catalent announced on October 8, 2025 a global, non-exclusive license allowing Catalent to incorporate Lisata’s certepetide and analogs into ADCs developed with Catalent’s SMARTag® platform.
Catalent gains worldwide rights to evaluate certepetide as SMARTag® payloads across multiple ADCs and may partner third parties. Lisata is eligible for over $10 million in tiered study-initiation milestone payments plus revenue sharing on future sales and partnerships. Catalent’s preclinical data provide proof-of-concept that iRGD peptides can improve ADC efficacy and pharmacokinetics; related preclinical work will be highlighted at the November World ADC conference in San Diego.
Lisata Therapeutics (Nasdaq: LSTA) reported encouraging preliminary results from the pancreatic cancer (PDAC) cohort of its Phase 1/2a CENDIFOX trial, evaluating certepetide in combination with FOLFIRINOX-based therapies. The trial, led by Dr. Anup Kasi at KU Cancer Center, showed promising outcomes in treating resectable and borderline resectable PDAC.
Key findings from the 35-patient PDAC cohort include: 50% R0 resection rate and 70% pathologic partial response among the 10 patients who completed pre-surgical therapy. The study demonstrated a 60% two-year overall survival rate and 12-month median disease-free survival. Importantly, the combination therapy showed enhanced immune cell infiltration and increased expression of immune markers, suggesting potential transformation of pancreatic tumors from "immune-cold" to "immune-hot."
Lisata Therapeutics (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and serious diseases, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
The company's President and CEO, David J. Mazzo, Ph.D., will deliver a pre-recorded corporate overview presentation, which will be available on-demand starting September 5, 2025, at 7:00 a.m. ET. The conference is scheduled to take place in New York City from September 8-10, 2025.